Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis (Pharmacology Notes) (Drug Overview)

Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis (Pharmacology Notes) (Drug Overview)

Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a recombinant form of human activated protein C. It was approved by the Food and Drug Administration in the last quarter of 2001 for the reduction of mortality due to severe sepsis in adult patients who are at high risk of death (1). This […]

Activated Protein C Resistance and Factor V Leiden: A Review (Report)

Activated Protein C Resistance and Factor V Leiden: A Review (Report)

Factor V Leiden (FVL) describes a G1691A nucleotide transition resulting in an R506Q amino acid missense mutation. Early papers showed that the resulting factor V protein was resistant to proteolysis by activated protein C (APC), and it is now recognized that FVL accounts for 90% to 95% of cases of APC resistance. Factor V resistance […]